Athira Pharma, Inc. - Common Stock (NQ:ATHA)

6.750 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Athira Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

November 28, 2022

HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS

From Athira Pharma, Inc.

Via GlobeNewswire

Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 21, 2022

Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration

From Athira Pharma, Inc.

Via GlobeNewswire

Around $4 Million Bet On Lesaka Technologies? Check Out These 4 Penny Stocks Insiders Are Buying ↗

November 18, 2022

US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

Athira Outlines Possible Comeback For Alzheimer's Candidate ↗

September 06, 2022

Via Benzinga

Athira Pharma: Q2 Earnings Insights ↗

August 15, 2022

Athira Pharma (NASDAQ:ATHA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference

November 16, 2022

From Athira Pharma, Inc.

Via GlobeNewswire

Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

November 10, 2022

From Athira Pharma, Inc.

Via GlobeNewswire

Athira Pharma to Present at Stifel 2022 Healthcare Conference

November 09, 2022

From Athira Pharma, Inc.

Via GlobeNewswire

4 Analysts Have This to Say About Athira Pharma ↗

June 23, 2022

Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter:

Via Benzinga

Athira Pharma Shares Fall To 52-Week Low - Read Why ↗

June 22, 2022

Via Benzinga

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference

November 07, 2022

Data supports neuroprotective and disease modifying potential in models of Parkinson’s disease and diabetic neuropathy

From Athira Pharma, Inc.

Via GlobeNewswire

Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis

October 17, 2022

From Athira Pharma, Inc.

Via GlobeNewswire

The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study ↗

July 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 ↗

July 07, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗

June 23, 2022

Upgrades

Via Benzinga

10 Biggest Price Target Changes For Thursday: Alcoa, Travelers And More ↗

June 23, 2022

Morgan Stanley cut Westinghouse Air Brake Technologies Corporation (NYSE: WAB) price target from $113 to $94. Westinghouse Air Brake Technologies shares fell 1.7% to $82.36 in pre-market trading.

Via Benzinga

76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More ↗

June 23, 2022

Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.

Via Benzinga

Dow Jumps 150 Points; Ocean Bio-Chem Shares Spike Higher ↗

June 22, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday.

Via Benzinga

Stocks Quietly Higher as Market Attempts to Extend Rally ↗

June 22, 2022

Stocks are modestly higher at midday.

Via Talk Markets

U.S. Stocks Turn Higher; Athira Pharma Shares Plummet ↗

June 22, 2022

U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 30 points on Wednesday.

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

June 22, 2022

Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.

Via Benzinga

Exela Technologies (XELA) Stock Soars After Securing $136 Million Contract ↗

June 22, 2022

Exela Technologies (XELA) stock is taking off on Wednesday after gaining a new $136 million customer contract that lasts for three years.

Via InvestorPlace

Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results ↗

June 22, 2022

Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton.

Via InvestorPlace

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗

June 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Athira Pharma Stock Is Plunging ↗

June 22, 2022

Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate...

Via Benzinga

ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA

May 27, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 20, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022 ↗

May 10, 2022

Upgrades

Via Benzinga

ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA

May 05, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

ATHIRA PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Athira Pharma, Inc. - ATHA

April 29, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.